much, Thank very Chris. you
announced strong with after already tenure busy, plan This I'm achievements CEO seventh balance line shortly have the were in as by quarter sheet. milestone to future the my my MosaiQ again, technology ensuring our been of in Once both we began report I role. very while of happy Quotient, we the another company represents that set which advancing of and supplementing our the
so just in history From opportunity, is the well of exploit a best us, prepared commercial in the position in technology financial and to the company's are and perspective, we which speak. front to
we the to access quarter, and our very those hear field late progress With X-month SDS an U.S. the set application and on microarray data results trial expectations, results December, completed such for SDS U.S. SDS approval key reviews. quarter notified the which microarray into they late menu filing This initial access, from filed now the and strong the June, body in Administration a mark will trial. Having is for was it's So the because accelerate let application market SDS approved, the from respect important the based once expansion showed with our both European instrument. for how European earlier market. initial to this the in customer step hands-on for our we Food long-term in review field the microarray market within a of initial fit MosaiQ MosaiQ completed originally filing, initial and our the we a and elements CE and Drug we our third plans. U.S. first the with critical for expect XXX(k) which the U.S. X- filed me to The in experience
testing for environment and high amplification instrument several Also which low-cost creation test. again, detection bar upon of study comparing third-party set multiplexing single environment viruses using the microarray certified a extraction standard was We any test cobas high conducted we solution, in Once is to effectiveness of platform. proprietary Switzerland. the our to this platform. in on feasibility ourselves automation. ISO in run performance quarter, a of MosaiQ our target preparations assays in manufactured of in the our with microarrays The a molecular molecular sample prototype testing our the using in December, using a completed our study industry-leading A manufacturing the Roche and X permits model proprietary used was by Eysins, a demonstrate throughput reported a
of in cross positive, risks X one and in were that false we microarray. multiplexes which XXX% and a of individual cobas big between is on This specificity. XX% are we spectacular. saw when talk the lack results the assays diagnostics with assays no where saw Given Interference means we development, points the concordance between to none.
has prototype once, such testing. to the engineers of represents loads. known these improve is of of contributing study. the product. is our negative tested in measures are final Sensitivity multiple and known that testing random known variability samples on nature Sensitivity samples we It XX.X% the studies the is varying in which positive, to was over other disease an our false MosaiQ butter. than that positives the which for the design. occurring and those XX%. bread least development times viral that the This orientation microarray common the to to hand supplemented in occurrence be course to And It of the then positive know is the in that to around the also engineering positive team's challenge, rather points that diagnostic sensitivity sample known at the by targeted model preparation the detects is all
plans validation intervening a for Our a approximately be that sample designing MosaiQ device. modified scalable beside our will now, a in reliable and model from within or call preparation and and XX work on study months focus verification period, to
available So solution multi-modality we the the results encouraged feel which diagnostics very high once again multiplexing be our of automated only today. underpins by claim for study, seminal the to throughput
while testing high tests. throughput on a new and delivering just help out We costs to invent laboratories diagnostics. don't productivity, existing empower automation of we tests taking Remember, platform repackage the
just verification be completed initial study microarray the IH often performance all commercial menu that conference. unique was have bankers also. As the Bank's microarray over we combination expanded and great for IH expanded IH in on the quarter, are and I deliver microarray validation on the said, Annual hosts before comprehensive world. plus antigen making progress that the approach will the of Having profile data AABB Blood overwhelmingly SDS the first American front blood automated from feedback published data the MosaiQ Association on we Customer and the a positive. to expanded
expanded we for Following trial commenced menu. IH validation study, this European the activities field
trials the both processes means manual particular, to these MosaiQ's results in is results in Leading Therefore, we order it the pace Part is take to to for up is CE comprehensive files, of the performance comparing to technical at MosaiQ's following to of applications trial product, IH remember IH expanded the menu do be the with results. capacity XX to modular and this of finalized. which trial consider derived technology up of to concordance. some automated expanded in field the automated on larger and manual speed This will worked design determine be a that can compared critical Even to day. underpin important mark trial predicate are only field order we As test our limited to testing in that antigen performed from once the longer compensate the field have than per labs follow-up the or donations file trial. previous to strategy this our which then fashion. with antigen data a up
about end So the this and time the the an modular first IH yes, initial the of filing approval which we to for have European calendar initial of and talked our by of year. includes approach, our subject menu IH control, calendar the to a market of expanded plan powerful year, SDS combination out this regulatory uncertainties approved in first initial, in direct expanded is half menu line,
be testing laboratories and lower donor grouping providers walkaway replacement replaced XX% platform resources with standardization this for simplification, with will in the all is initial MosaiQ and with manual of be can world. provide scarce care objective the the [indiscernible] strategy of comprehensive competitive a cost blood products of saving blood one proposition valuable Our menu will highly blood the platforms through menu and system. health health believe over more automation care market. about a Two organizations of most to competitive available product of all and attractive combination. We plot very characterized the this in
on made is businesses. we next have our In past, organically, also have in with our it alignment organization on While focused had long we Not evolution. and over organizational this the common taking this -- for led development, as CEO, execution entrepreneur some progress I stage wanted talents also the growth and on which what after of key are grown organizational next rapid my year But skills, be to a first more needed to sustainable add me and it to obviously missing. focus to we stewardship, good create was to obvious structure. done in
with work done, simplify side certain to good the this X development and redefine of was on design It organization although year. spans recently the to and cost of with specifically This leaders. layers plants flatter rollout last With for with and to commercialization in a over and the we and business, will some This Broader savings. be momentum removed responsive accumulated functions. accountability of work began control enhanced organization X months. new organization agile the empowerment work a done have not was this costs, and the later were there save of more in the done
connection step In very Officer Chief lead to the pleased our created to the plans. have transformation, execution Farrell this day-to-day Operating into Ed I'm with role of newly of
business continues brilliantly shine with Lastly, XX% sales almost growing to our reagent for year-to-date. product the
around OEM from the team both benefit its profit triggering of key time, million, credentials, transfusion from this the a our approvals total, operating successfully from apart diagnostics for payment of we new milestone customers very world. business injection addition, regulators and -- regulatory products moving over in In forward, with $X.X increased welcome also deep
in He it it our interests goal with and retirement to Chris time function. that company well Chris' a on from announced had for while very his as full-time strong footing a of is focus us accomplished the that the Chris of to was spend and very this leave U.S., family job done, lead able control is the until Buller, CFO. put to found his Lastly, would we therefore, month to earlier financial Peter came Lindop, to he Chris. always a the the time mixed mission boat where to we company's I financing retirement year CFO. this later to be made as help solid I is continue have successor to was, successor now feeling, clear not out say, announce Chris this to second based. outcome and he delighted on employment more retiring that
of around XX over the international extensive Peter He search, health leadership is based own found door. Swiss experience to world. will years' care with right technology our take in financial an and the Peter After national his and a X, responsibility we has a companies on agreed consultancy next an Chris speak, backyard, in until to to basis May. of Executive February priorities serve strategic retirement, will also Post his end Chris to various reporting as the on on as needed. available retirement President at and working me be transition Vice so
Chief outgoing our With me that, Chris, hand the Officer. let Chris? over Financial to call
